

**AMENDMENTS TO THE SPECIFICATION:**

Please amend the paragraph beginning at page 5, line 31, as follows:

In some preferred embodiments, a preS1 (94-117) peptide may have the following amino acid sequence;

**PX<sub>1</sub>STNRQSGRQPTPX<sub>2</sub>SPPLRX<sub>3</sub>X<sub>4</sub>HP** (SEQ ID NO:1)

where X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub> and X<sub>4</sub> may be any amino acid.

Please amend the paragraph beginning at page 6, line 8, as follows:

In some especially preferred embodiments, a preS1 (94-117) peptide may have one of the following sequences (X<sub>1</sub>, X<sub>2</sub> and X<sub>3</sub> shown in bold);

(i) PASTNRQSGRQPTPLSPPLRN**THP** (SEQ ID NO:2)

(ii) PASTNRQSGRQPTPLSPPLRT**THP** (SEQ ID NO:3)

(iii) PASTNRQSGRQPTPIS**PPLRDSHP** (SEQ ID NO:4)

Please amend the paragraph beginning at page 17, line 17, as follows:

A peptide consisting of the preS1#94-117 sequence of the HBV subtypes *adw*, *adw*<sub>2</sub> and two out of three described *adr* subtypes (i.e. PASTNRQSGRQPTPIS**PPLRDSHP**) (SEQ ID NO:4) were obtained from Sigma Genosys, London Road, Cambridge, UK. The peptide was supplied lyophilized, resuspended in sterile distilled water and kept at -20°C. The purity was >95% by HPLC.

Before the Figures, insert the Sequence Listing submitted herewith.